Cytosorbents Corp (CTSO)

• Market cap: $64.4M
• 1 day: 0.98%
• 5 days: 10.69%
• 1 month: -8.85%
• 3 months: 0.00%
• 6 months: -8.85%
• Year to date: 11.96%
• 1 year: 30.38%
• 5 years: -86.86%
• 10 years: -86.17%
• Sector: Healthcare
• Industry: Medical Devices

About: CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Employees: 149

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

2% less funds holding

Funds holding: 52 [Q3] → 51 (-1) [Q4]

2.23% less ownership

Funds ownership: 30.18% [Q3] → 27.96% (-2.23%) [Q4]

42% less capital invested

Capital invested by funds: $24.6M [Q3] → $14.2M (-$10.4M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1 3% downside
• Avg. target: $5.50 434% upside
• High target: $10 871% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

HC Wainwright & Co. Sean Lee 48% 1-year accuracy 14 / 29 met price target	3% downside $1	Neutral Reiterated	3 Apr 2025
D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target	871% upside $10	Buy Maintained	1 Apr 2025